Cellectis (CLLS) Cash from Operations Growth (5y) (2020 - 2026)

Cellectis (CLLS) Cash from Operations Growth (5y) (2020 - 2026) Analysis & Trends

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Oculis Holding AG 68,785.72 Bn 68,785.72 Bn -
2 Nanobiotix 1,895.57 Bn 1,895.51 Bn -
3 BeOne Medicines 471.35 Bn 466.56 Bn 1.35 Bn
4 NuCana 279.75 Bn 279.75 Bn -
5 Vertex Pharmaceuticals 120.24 Bn 113.00 Bn 2.59 Bn
6 Regeneron Pharmaceuticals 67.80 Bn 59.04 Bn 3.31 Bn
7 Belite Bio 62.51 Bn 62.51 Bn -
8 Argenx Se 57.38 Bn 57.38 Bn 1.41 Bn
9 Revolution Medicines 37.78 Bn 37.78 Bn -
10 Cellectis 281.48 Mn 95.81 Mn -

Historic Data

Download Data
DateValue
Mar 31, 2026 17.75%
Dec 31, 2025 -28.28%
Sep 30, 2025 42.78%
Jun 30, 2025 14.24%
Mar 31, 2025 -68.96%
Dec 31, 2024 63.56%
Sep 30, 2024 23.77%
Jun 30, 2024 34.85%
Mar 31, 2024 -0.81%
Dec 31, 2023 30.27%
Sep 30, 2023 -2.63%
Jun 30, 2023 -6.73%
Mar 31, 2023 -5.69%
Dec 31, 2022 17.47%
Sep 30, 2022 -8.11%
Jun 30, 2022 -11.02%
Mar 31, 2022 -12.83%
Dec 31, 2021 -77.58%
Sep 30, 2021 -74.02%
Jun 30, 2021 -2.45%